217 related articles for article (PubMed ID: 19933807)
21. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.
Sime FB; Stuart J; Butler J; Starr T; Wallis SC; Pandey S; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581122
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
25. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
28. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
[TBL] [Abstract][Full Text] [Related]
29. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
Robatel C; Rusca M; Padoin C; Marchetti O; Liaudet L; Buclin T
J Antimicrob Chemother; 2004 Jul; 54(1):269-70. PubMed ID: 15175271
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
31. Treatment of refractory cerebral aspergillosis in a liver transplant recipient with voriconazole: case report and review of the literature.
Cherian T; Giakoustidis A; Yokoyama S; Heneghan M; O'Grady J; Rela M; Wendon J; Heaton DN; Verma A
Exp Clin Transplant; 2012 Oct; 10(5):482-6. PubMed ID: 23031086
[TBL] [Abstract][Full Text] [Related]
32. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
[TBL] [Abstract][Full Text] [Related]
33. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Liu P; Foster G; Labadie R; Somoza E; Sharma A
Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
[TBL] [Abstract][Full Text] [Related]
35. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
[TBL] [Abstract][Full Text] [Related]
36. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
38. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.
Pai MP; Lodise TP
Antimicrob Agents Chemother; 2011 Jun; 55(6):2601-5. PubMed ID: 21422207
[TBL] [Abstract][Full Text] [Related]
39. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
[TBL] [Abstract][Full Text] [Related]
40. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
